• 1
    Tannock IF, de Wit R, Berry W et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 2
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 3
    Chi KN, Bjartell A, Dearnaley D et al. Castration resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594605
  • 4
    Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23: 824752
  • 5
    Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20: 8916
  • 6
    Ross RW, Beer TM, Jacobus S et al. A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112: 5216
  • 7
    Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 108996
  • 8
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 1999; 17: 34617
  • 9
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516
  • 10
    National Cancer Institute. Common Toxicity Criteria for Adverse Events, Version 3.0. 2003. Available at: Accessed October 2009
  • 11
    Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 45781
  • 12
    Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296300
  • 13
    James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone- resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 111223
  • 14
    Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 456371
  • 15
    Scher HI, Halabi S, Tannock I et al. Design and end-points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 114859
  • 16
    Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195208